Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chugai Hemophilia Drug, Novel Zoster Vaccine Set for Approval Review on March 2
February 19, 2018
- Nobelpharma’s Sakigake-Designated Sirolimus Gel Up for MHLW Panel Review on March 1
February 19, 2018
- Harvoni Approved for Genotype 2 Hep C, Zytiga for Earlier Line
February 19, 2018
- PhRMA Wants Japan Put on “Priority Watch List” in USTR’s Trade Barrier Report
February 16, 2018
- MHLW OKs Authorized Generics for Aimix, Cravit IV, Takepron; June Listing Eyed
February 16, 2018
- 20 Gx Makers Flock to Aimix, Sawai Earns Approval for Tamiflu Copy for June Listing
February 16, 2018
- MHLW Launches Startup Support Project
February 16, 2018
- MHLW Looked at Balance and Made Major Revision Plans for Drug Pricing: Official
February 14, 2018
- Label Revisions Ordered for Gardenia Fruit Kampo Agents, Stocrin
February 14, 2018
- Japan Cabinet Adopts Bill to Require Generic Use for Welfare Recipients
February 13, 2018
- Payers Give High Marks for “Bold” Pricing Reform, but Not Happy with PMP
February 8, 2018
- Chuikyo Submits Recommendation for FY2018 Reimbursement Policy Reform, Drug Pricing Package Enshrined
February 8, 2018
- MHLW Notifies of Revisions of Ministerial Ordinances to Prevent Distribution of Counterfeit Drugs
February 7, 2018
- Japan’s 1st Herceptin Biosimilar Clears MHLW Panel, Now in Line for March Approval for Gastric Cancer
February 5, 2018
- MHLW Panel Backs “Sakigake” Influenza Drug; Possibility of Accelerated Approval and Listing Unclear
February 5, 2018
- MHLW Cautions on Hepatitis E Virus Infection due to Blood Products for Transfusion
February 2, 2018
- MHLW Panel Calls for Single-Product, Single-Price Transactions for Blood Products
February 2, 2018
- Proper Use of Ethical Moisturizing Agents Added to Supplementary Opinion for FY2018 Reimbursement Reform: Chuikyo
February 1, 2018
- Drug Pricing Reform Draws Mixed Opinions: Public Comments
February 1, 2018
- Drug Makers Looking to Adopt Continuous Manufacturing, Anticipating 30-40% Lower Production Costs: PMDA Official
January 31, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…